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ABSTRACT
Objectives: The purpose of this systematic review was to assess the efficacy of
rowth hormone (GH) treatment in patients with short bowel syndrome (SBS).
Methods: Electronic searches were performed to identify all publications de-
cribing randomized controlled trials (RCTs) on the use of GH with or without
lutamine for the treatment of patients with SBS. The outcomes of interest were body
eight, lean body mass, and intestinal absorption function.
Results: Four trials involving 70 patients were included in the review. A
eta-analysis of these trials suggested that GH had a positive effect in terms of
ncreased weight (mean difference [MD]  1.66; 95% CI, 0.69–2.63, P  0.001),
ean body mass (MD  1.93; 95% CI, 0.97–2.90; P  0.001), energy absorption
MD  4.42; 95% CI, 0.26–8.58; P  0.04), nitrogen absorption (MD  4.85;
5% CI, 0.20–9.49; P 0.04), and fat absorption (MD 5.02; 95% CI, 0.21–9.82;
 0.04) for patients with SBS. Adverse effects occurred during active treatment in
ll trials. Only 1 trial included a 12-week follow-up study.
Conclusions: The results suggest a possible short-term benefit in terms of
ody weight, lean body mass, and absorptive capacities; however, no conclusion of
ong-term efficacy of GH could be obtained. Large-scale, long-term follow-up RCTs
re needed to confirm the efficacy and tolerability of GH in the future. (Curr Ther Res
lin Exp. 2011;72:109-119) © 2011 Elsevier HS Journals, Inc. All rights reserved.
Key words: growth hormone, meta-analysis, randomized controlled trial,
short bowel syndrome, systematic review.
INTRODUCTION
Short bowel syndrome (SBS) is characterized by the inability to maintain protein
energy, fluid, electrolyte, or micronutrient balances when on a conventionally ac-
cepted, normal diet. SBS results in chronic diarrhea, dehydration, fluid and electrolyte
imbalances, and malnutrition.1 Patients with SBS often require long-term parenteral
utrition (PN) to maintain daily nutritional requirements until the residual intestine
ndergoes adaptation and nutritional autonomy is obtained. However, the use of
Accepted for publication April 5, 2011. doi:10.1016/j.curtheres.2011.04.002
2011 Elsevier HS Journals, Inc. All rights reserved. 0011-393X/$ - see front matter
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Current Therapeutic Researchlong-term PN is expensive and associated with certain complications, including
venous occlusions, catheter sepsis, and liver failure.2–5
Although intestinal transplantation is the ideal option for patients with SBS, this
urgery presents several problems. The long-term survival rate of intestinal trans-
lantation is not high enough to be accepted as a routine procedure for clinical
herapy. Since a program of intestinal rehabilitation, which included growth hormone
GH), glutamine, and a modified diet, was proposed by Byrne et al6 to enhance
intestinal compensation and attenuate intestinal failure, several clinical trials have
been performed, with controversial results.7–13 Some observers suggested that pa-
ients who depended on PN could be weaned after bowel rehabilitation therapy,
hereas others asserted that data were inconclusive and that more trials were war-
anted.
To assess the efficacy and safety of GH in patients with SBS, a system review was
erformed with meta-analysis of relevant randomized controlled trials (RCTs).
METHODS
Search Strategy
The study was conducted with a specified search strategy and eligibility criteria.
n extensive electronic search of PubMed (1966 to April 30, 2010), the Science
itation Index (1900 to April 30, 2010), and the Cochrane Central Register of
ontrolled Trials (to The Cochrane Library Issue 4, 2010) was performed to identify
elevant RCTs for the meta-analysis. Searches were limited to published English
anguage articles. Search term combinations were “growth hormone” and “short
owel syndrome.” All reference lists from the relevant articles and reviews were
earched for additional relevant studies. Unavailable articles were requested from the
uthors.
Inclusion and Exclusion Criteria
Two reviewers independently searched the literature for relevant clinical RCTs that
ncluded patients of all ages diagnosed with SBS (defined as “a condition of malab-
orption and malnutrition resulting from the loss of absorptive surface area following
assive small bowel resection”).1 Trials were eligible if they reported specific data on
hanges in body weight, lean body mass, intestinal absorption function (energy,
itrogen, fat, and carbohydrate), and adverse effects. Reviewers assessed method of
andomization, allocation concealment, patient demographic characteristics, blinding
f participants and outcome assessors, intention-to-treat analysis, interventions, num-
er of patients lost to follow up, trial outcomes, and whether follow-up evaluations
ere conducted for methodological and trial design quality. Both blinded and
pen-design trials were eligible.
Reviews, case reports, experimental studies, unpublished data, articles not avail-
ble for review, and results from non-RCTs were excluded from consideration.
Trial assessment discrepancies between the reviewers were resolved by consensus orhird-party intervention.
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M.-X. Guo et al.Statistical Analysis
Statistical analysis was performed using RevMan 5 software (Cochrane IMS, Oxford,
nited Kingdom). Follmann’s method was used for crossover studies. A correlation
oefficient of 0.4 was used to calculate the standard error (SE) of the mean difference (MD).
he quantities of the MD and the SE of the MD were then entered into RevMan and
nalyzed using a generic inverse variance outcome. Heterogeneity between trial results
as tested using a standard 2 test. A fixed-effect approach was used unless there was
ubstantial heterogeneity, in which case a random effects approach was used and the
otential causes of heterogeneity examined.
RESULTS
Study Characteristics
We identified 233 reports through database searches, all of which were published
nd available via the Internet. Of these, 225 were rejected after review of the abstracts
ndicated that they were not RCTs or that they tested an intervention other than GH.
inally, 8 reports were assessed in full text; 7 were preliminarily included and 1 trial6
was excluded because of it nonrandomized design. Of the remaining 7 reports, 27,11
were excluded for lack of detailed data on results and 113 was rejected as a secondary
ublication reporting revised outcomes of a previous study.12 Four relevant studies
Figure 1. Flow diagram of the randomized controlled trials reviewed. GH  growth hor-
mone.were finally identified, involving a total of 70 participants (Figure 1)8–10,12 All trial
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Current Therapeutic Researchresults were published between 1997 and 2005. Table I presents the demographic
characteristics of the trial participants and interventions of RCTs included in the
meta-analysis.
All studies enrolled were double-blind placebo-controlled trials. The dose of GH
used in these trials ranged from 0.05 to 0.14 mg/kg/d. The duration of treatment in
2 trials (low-dose GH alone, 0.05 mg/kg/d) was 3 and 8 weeks, respectively.8,10 The
uration of treatment in 2 other trials (high-dose GH, 0.1 and 0.14 mg/kg/d,
espectively, plus other treatment with oral glutamine and/or modified diet) was 4
eeks.9,12 Only 1 trial conducted a 12-week follow-up study, which included
hysical examination, nutritional history, and blood studies9; no one was lost to
ollow up. There were no deaths in any trial.
Quality Assessment
Based on current standards, the methodological quality of all included trials was
uboptimal. Allocation concealment was adequately described in all results. Although
ll trials used the random method, only 1 trial allocated patients by random num-
er10; 3 other trials did not identify the method of randomization. The possibility of
election bias and performance bias, therefore, could not be excluded. All trials were
ouble-blinded, and 19 reported an intention-to-treat analysis.
Analysis of the Efficacy and Tolerability of Treatment
Body Weight
In their study of GH to treat SBS, Byrne et al9 found that body weight increased
from pretreatment (screening) to end of treatment and decreased at the end of follow
up, but there was no clear difference between treatment groups. Further, the average
body weights for groups remained within 3% of ideal body weight at the end of
follow up.9 The data were pooled from 3 crossover trials for the purpose of meta-
analysis.8,10,12 The results showed that GH, with or without glutamine, improved
body weight significantly at the end of treatment (MD  1.66; 95% CI, 0.69–2.63;
P  0.001) (Figure 2) in adults patients with SBS.
Lean Body Mass
Pooled estimates were calculated for 3 studies,8,10,12 and results revealed that GH,
ith or without glutamine, significantly improved lean body mass at the end of
reatment (MD 1.93; 95% CI, 0.97–2.90; P 0.001) (Figure 3) in adult patients
with SBS.
Absorption Function Assessment
The meta-analysis results showed that low-dose GH had a positive effect on
intestinal absorption, whereas high-dose GH did not improve intestinal absorption.
The pooled analysis showed a statistically significant effect of the treatment on
increasing energy absorption (MD  4.42; 95% CI, 0.26–8.58; P  0.04) (Figure
4), nitrogen absorption (MD 4.85; 95% CI, 0.20–9.49; P 0.04) (Figure 5), and
fat absorption (MD  5.02; 95% CI, 0.21–9.82; P  0.04) (Figure 6). However,
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Table I. Main demographic characteristics of the trials included in the meta-analysis.
Author Year
Demographic Characteristics Methodology Intervention
Follow-up
Adverse
Events
Mean
Age,
y
Subjects,
n
Mean JI
Length,
cm
Colon
(yes/no) RM AC Blinding Treatment Control
Seguy et al8 2003 35 12 48 9/3 Yes Yes DB GH Placebo No Yes
Byrne9 2005 49 41 71 36/5 Yes Yes DB GH  other Placebo Yes Yes
Ellegard et al10 1997 49 10 130 4/6 Yes Yes DB GH Placebo No Yes
Szkudlarek et al12 2000 47 8 104 4/4 Yes Yes DB GH  other Placebo No Yes
AC  allocation concealment; DB  double-blinding; JI  jejunal-ileal; RM random method.
M
.-X
.
G
u
o
e
t
a
l
.
1
1
3
1A
t
Current Therapeutic Researchthere was no difference in carbohydrate absorption (MD  4.86; 95% CI –2.98 to
2.69; P  0.22) (Figure 7).
dverse Effects and Mortality Assessment
Adverse effects were reported in all trials. Peripheral edema was reported in 2
rials,9,12 with an overall frequency of 90%. Muscle discomfort was reported in 3
studies,8–10 with an overall frequency of 31.48%. Arthralgic discomfort was reported
in 3 studies,8–10 with a total occurrence probability of 33.33%. Other, minor,
complications included gastrointestinal discomfort, transient gynecomastia, and
Treatment
Study or Subgroup
1.1.1 Low-dose group
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
1.1.2 High-dose group
Ellegard et al10 1.6 0.77
0.65 1.39
10 10 41.3% 1.60 (0.09 to 3.11)
8 8
–10 –5
Favors treatment Favors control
5 100
12.7% 0.65 (–2.07 to 3.37)
2 0.73 12 12 46.0% 2.00 (0.57 to 3.43)
22 22 87.3% 1.81 (0.77 to 2.85)
8 8 12.7% 0.65 (–2.07 to 3.37)
30 30 100.0% 1.66 (0.69 to 2.63)
Heterogeneity: c2 = 0.14, df = 1 (P = 0.71); I2 = 0%
Test for overall effect: Z = 3.42 (P = 0.006)
Seguy et al8
Szkudlarek et al12
Heterogeneity: Not applicable
Heterogeneity: c2 = 0.75, df = 2 (P = 0.69); I2 = 0%
Test for overall effect: Z = 3.36 (P = 0.008)
Test for subgroup differences: c2 = 0.61, df = 1 (P = 0.44), I2 = 0%
Test for overall effect: Z = 0.47 (P = 0.64)
Mean Difference SE Total Total Weight
Mean Difference
IV, Fixed, 95% CI
Mean Difference
IV, Fixed, 95% CI
Control
Figure 2. Forest plot comparing body weight (kilograms) between growth hormone with or
without glutamine versus placebo. df  degrees of freedom. IV  inverse
variance.
Treatment
Study or Subgroup
1.1.1 Low-dose group
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
1.1.2 High-dose group
Ellegard et al10 1.8 0.86
1.43 1.02
10 10 32.7% 1.80 (0.11 to 3.49)
8 8
–10 –5
Favors treatment Favors control
5 100
23.2% 1.43 (–0.57 to 3.43)
2.3 0.74 12 12 44.1% 2.30 (0.85 to 3.75)
22 22 76.8% 2.09 (0.99 to 3.19)
8 8 23.2% 1.43 (–0.57 to 3.43)
30 30 100.0% 1.93 (0.97 to 2.90)
Heterogeneity: c2 = 0.19, df = 1 (P = 0.66); I2 = 0%
Test for overall effect: Z = 3.72 (P < 0.001)
Seguy et al8
Szkudlarek et al12
Heterogeneity: Not applicable
Heterogeneity: c2 = 0.51, df = 2 (P = 0.77); I2 = 0%
Test for overall effect: Z = 3.94 (P < 0.001)
Test for subgroup differences: c2 = 0.32, df = 1 (P = 0.57), I2 = 0%
Test for overall effect: Z = 1.40 (P = 0.16)
Mean Difference SE Total Total Weight
Mean Difference
IV, Fixed, 95% CI
Mean Difference
IV, Fixed, 95% CI
Control
Figure 3. Forest plot comparing lean body mass (kilograms) between growth hormone
with or without glutamine versus placebo. df degrees of freedom. IV inverse
variance.
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M.-X. Guo et al.nightmares. With discontinuation of GH, symptoms related to the drug resolved in
all patients. There were no deaths in any trial, and quality of life was not assessed in
this review.
DISCUSSION
Post-resection intestinal adaptation is complex and influenced by several factors, and
management of patients with SBS is challenging and requires vigorous attention to
every detail. Several trophic factors, such as GH and glutamine, that can promote
adaptation of the remnant intestine have been identified in a number of animal
experiments and clinical trials.
Treatment
Study or Subgroup
1.1.1 Low-dose group
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
1.1.2 High-dose group
Ellegard et al10 3 2.07
2 1.96
10 10 36.5% 3.00 (–1.06 to 7.06)
8 8
–20 –10
Favors treatment Favors control
10 200
37.8% 2.00 (–1.84 to 5.84)
10 3.08 12 12 25.7% 10.00 (3.96 to 16.04)
22 22 62.2% 6.13 (–0.69 to 12.95)
8 8 37.8% 1.43 (–1.84 to 5.84)
30 30 100.0% 4.42 (0.26 to 8.58)
Heterogeneity: t2 = 17.61; c2 = 3.56, df = 1 (P = 0.66); I2 = 72%
Test for overall effect: Z = 1.76 (P = 0.08)
Seguy et al8
Szkudlarek et al12
Heterogeneity: Not applicable
Heterogeneity: t2 = 8.09; c2 = 5.04, df = 2 (P = 0.08); I2 = 0%
Test for overall effect: Z = 2.08 (P = 0.04)
Test for subgroup differences: c2 = 1.49, df = 1 (P = 0.22), I2 = 32.7%
Test for overall effect: Z = 1.02 (P = 0.31)
Mean Difference SE Total Total Weight
Mean Difference
IV, Random, 95% CI
Mean Difference
IV, Random, 95% CI
Control
Figure 4. Forest plot comparing energy absorption (kilocalories) between growth hormone
with or without glutamine versus placebo. df degrees of freedom. IV inverse
variance.
Treatment
Study or Subgroup
1.1.1 Low-dose group
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
1.1.2 High-dose group
Ellegard et al10 3 2.07
1 4.58
10 10 43.9% 3.00 (–1.06 to 7.06)
8 8
–100 –50
Favors treatment Favors control
50 1000
19.0% 1.00 (–7.98 to 9.98)
9 2.57 12 12 37.1% 9.00 (3.96 to 14.04)
22 22 81.0% 5.81 (–0.06 to 11.67)
8 8 19.0% 1.00 (–7.98 to 9.98)
30 30 100.0% 4.85 (0.20 to 9.49)
Heterogeneity: t2 = 12.56; c2 = 3.31, df = 1 (P = 0.07); I2 = 70%
Test for overall effect: Z = 1.94 (P = 0.05)
Seguy et al8
Szkudlarek et al12
Heterogeneity: Not applicable
Heterogeneity: t2 = 8.51; c2 = 4.11, df = 2 (P = 0.13); I2 = 51%
Test for overall effect: Z = 2.05 (P = 0.04)
Test for subgroup differences: c2 = 0.81, df = 1 (P = 0.37), I2 = 0%
Test for overall effect: Z = 0.22 (P = 0.83)
Mean Difference SE Total Total Weight
Mean Difference
IV, Random, 95% CI
Mean Difference
IV, Random, 95% CI
Control
Figure 5. Forest plot comparing nitrogen absorption (grams) between growth hormone
with or without glutamine versus placebo. df degrees of freedom. IV inverse
variance.
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Current Therapeutic ResearchGH is a protein-based peptide hormone that promotes somatic growth, stimulates
rotein synthesis, and regulates carbohydrate and lipid metabolism. In rodent sys-
ems, GH administration resulted in an increase in small bowel length and function
er unit length.14 Moreover, the exogenous administration of GH was reported to
have positive effects on mucosal growth and intestinal adaptation after massive
resection in animals.15 In addition, insulin-like growth factor-1, which is regulated
y GH, was shown to enhance intestinal hyperplasia and hypertrophy in rats after
assive intestinal resection.16 Additionally, exogenous GH had a positive effect on
ransport velocity of amino acids in ileum and duodenal crypt cell proliferation of
ultured human explants in humans.17,18
Treatment
Study or Subgroup
1.1.1 Low-dose group
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
1.1.2 High-dose group
Seguy et al8 8 3.09
3 2.17
12 12 40.3% 8.00 (1.94 to 14.06)
8 8
–20 –10
Favors treatment Favors control
10 200
59.7% 3.00 (–1.25 to 7.25)
12 12 40.3% 8.00 (1.94 to 14.06)
8 8 59.7% 3.00 (–1.25 to 7.25)
20 20 100.0% 5.02 (0.21 to 9.82)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.59 (P = 0.010)
Szkudlarek et al12
Heterogeneity: Not applicable
Heterogeneity: t2 = 5.37; c2 = 1.75, df = 1 (P = 0.19); I2 = 43%
Test for overall effect: Z = 2.05 (P = 0.04)
Test for subgroup differences: c2 = 1.75, df = 1 (P = 0.19), I2 = 43.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Mean Difference SE Total Total Weight
Mean Difference
IV, Random, 95% CI
Mean Difference
IV, Random, 95% CI
Control
Figure 6. Forest plot comparing fat absorption (grams) between growth hormone with or
without glutamine versus placebo. df  degrees of freedom. IV  inverse
variance.
Figure 7. Forest plot comparing carbohydrate absorption (grams) between growth hor-
mone with or without glutamine versus placebo. df  degrees of freedom. IV 
inverse variance.
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M.-X. Guo et al.Glutamine is the primary fuel source for enterocytes. Supplemental glutamine was
hown to enhance the absorption of sodium and glucose and to prevent intestinal
trophy in humans who received PN therapy.19,20 Glutamine is also necessary for cell
signaling pathways when enterocytes are exposed to trophic factors.21 In addition,
GH has a synergistic effect on bowel uptake of glutamine.22 The combination of GH
nd glutamine, therefore, might have a positive effect on bowel morphology and
unction.
The use of GH in human clinical studies has been widely investigated, but the
ffect of the treatment on intestinal adaptation in patients with SBS is still de-
ated.7–10 In this systematic review, 4 RCTs on the efficacy and tolerability of GH,
with or without glutamine, in patients with SBS, were evaluated. The results of the
meta-analysis demonstrated an increase in weight, lean body mass, and absorptive
capacities at the end of therapy in these patients. In this review, quality of life and
nutritional status of patients with SBS at the end of follow up (at least 3 months) were
the primary indexes of long-term curative effects. However, only 1 trial conducted a
12-week follow-up study. The results showed a sustained reduction in PN volume,
calories, and number of infusions at the end of follow-up in patients who received
GH, glutamine, and diet manipulation, whereas body weight decreased from pre-
treatment screening to end of follow-up. Although administration of GH might
provide benefit in terms of weight gain and intestinal absorption at the end of
therapy, long-term efficacy of GH has not yet been determined.
Adverse effects were reported in all trials in this review. Fluid retention was the
major side effect of GH administration and was reported in 2 trials using high-dose
GH,9,12 although fluid retention did not occur and only minor side effects were
reported in the 2 trials using low-dose GH.8,10 Symptoms related to GH resolved in
ll patients at discontinuation of GH. Findings from the meta-analysis suggested that
ow-dose GH was more tolerable than high-dose GH.
In addition, there was a high degree of statistical heterogeneity among the study
esults investigated in the meta-analysis. There were several reasons for the inconsis-
ent results, such as variation in patient selection, drug dosage, use of glutamine,
ength of study, and method of assessing outcome.
In contrast to a previous meta-analysis,23 we examined 4 well-designed RCTs that
focused on the efficacy and safety of GH for patients with SBS. Although adminis-
tration of GH might provide benefit in terms of weight gain and intestinal absorption
at the end of therapy, the long-term efficacy of GH remains unknown. Furthermore,
given the small number of patients enrolled in these studies, the present results
should be interpreted with caution. Large-scale, long-term follow-up RCTs are
needed to confirm the efficacy and safety of GH in the treatment of SBS.
CONCLUSION
This systematic review suggests a possible short-term benefit in terms of body weight,
lean body mass and absorptive capacities. However, no conclusion of long-term
efficacy of GH could be obtained as yet. Given the small number of patients enrolled
in these studies, the present results should be interpreted with caution. Large-scale,
117
Current Therapeutic Researchlong-term follow-up RCTs are needed to confirm the efficacy and safety of GH
treatment in patients with SBS in the future.
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